{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-020383","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2023-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.895350+00:00","generated_at":"2026-06-13T04:53:56.437867+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AcelRx raises ~$10M via private placement of common stock and warrants","bullets":["Gross proceeds ~$10M from sale of 5.34M shares, pre-funded warrants for 2.01M shares, and Series A/B warrants for 7.35M shares each at $1.11 exercise price; combined price $1.36.","Closing expected July 20, 2023; placement agent H.C. Wainwright receives 5.25% fee, expense reimbursement up to $100k, and $200k if warrant exercise proceeds exceed $9.5M.","Registration rights agreement requires filing resale registration statement within 15 days, effectiveness within 90 days.","Series A/B warrants exercisable immediately, 5-year term; Series A term shortens to 45 days upon FDA EUA for Niyad; Series B term shortens upon successful registrational trial for Niyad."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-020383","json":"https://secwatch.observer/filing/0001437749-23-020383.json","markdown":"https://secwatch.observer/filing/0001437749-23-020383.md","text":"https://secwatch.observer/filing/0001437749-23-020383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923020383/0001437749-23-020383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923020383/acrx20230719_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:53:56.437867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86c6fb35373aa12e644bafa5059d7e8fcdbb8d2a","claim":"TALPHERA, INC. entered into Registration Rights Agreement with the Purchasers (effective 2023-07-17).","evidence_excerpt":"We entered into a registration rights agreement, dated July 17, 2023, with the Purchasers pursuant to which we have agreed to file a registration statement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923020383/0001437749-23-020383-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the Purchasers"},{"label":"Effective","value":"2023-07-17"}],"fact_type":"material_agreement"},{"claim_id":"91b294d586d87491875e3c962bc4a4b189965677","claim":"TALPHERA, INC. entered into Purchase Agreement with several institutional investors valued at approximately $10.0 million (effective 2023-07-17).","evidence_excerpt":"On July 17, 2023, AcelRx Pharmaceuticals, Inc., or AcelRx, entered into a securities purchase agreement, or the Purchase Agreement, with several institutional investors, or the Purchasers, relating to the issuance and sale to the Purchasers in a private placement of","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923020383/0001437749-23-020383-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"several institutional investors"},{"label":"Value","value":"approximately $10.0 million"},{"label":"Effective","value":"2023-07-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}